Kangbaida Biotechnology divulges new TLR7 and TLR8 antagonists
June 3, 2025
Kangbaida (Sichuan) Biotechnology Co. Ltd. has synthesized pyrrolidine derivatives acting as Toll-like receptor 7 (TLR7) and/or (TLR8) antagonists reported to be useful for the treatment of autoimmune disease.